Chris Parker, MD

Chris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.

Chris Parker, MD, discusses the rationale for the phase III RADICALS-RT trial in prostate cancer.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the results of the phase III RADICALS-RT trial in prostate cancer.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in patients with metastatic prostate cancer.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the rationale for radiotherapy in the treatment of newly-diagnosed metastatic prostate cancer.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.